Fermer le menu



Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses and diseases, announced today the appointment of Dr. Chris Martin to its Board of Directors. Dr. Martin brings with him over 20 years of experience in the pharmaceutical and biotech sector. He is an accomplished company founder and director who has successfully brought technology from the lab to regulatory approval and global markets. He joins Osivax as the company advances its lead candidate, OVX836, a Phase 2 first-in-class broad-spectrum influenza vaccine candidate through clinical evaluation and prepares to enter the clinic with its universal coronavirus vaccine candidate, OVX033.
“Chris’ extensive knowledge in the development and commercialization of new therapies coupled with his experience as a serial biotech entrepreneur will be a valuable asset to our team. We look forward to his contributions and insights as we continue advancing the development of our technology and pipeline,” commented Alexandre Le Vert, CEO and Co-Founder of Osivax. “We are deeply saddened by the loss of Dr. Mike Watson, who served on our Board of Directors with distinction. He will be greatly missed, but his legacy will continue to inspire us.” 


Read the press release

Plus d'infos